{"filings":[{"id":94392,"accession_number":"0001628280-26-030136","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rhythm Q1 product revenue $60.1M; IMCIVREE HO launch >150 start forms; net loss $(0.83)/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 net product revenue $60.1M (up 5% sequentially); U.S. revenue $36.9M, ex-U.S. $23.2M.","IMCIVREE received FDA approval for acquired hypothalamic obesity on Mar 19; >150 patient start forms in first six weeks.","European Commission granted marketing authorization for IMCIVREE in acquired HO on May 1, 2026.","Net loss $(56.7)M ($(0.83)/share) vs $(50.8)M ($(0.81)/share) in Q1 2025; cash $340.6M.","Phase 3 EMANATE trial missed primary endpoint; positive post-hoc signals in SRC1 and POMC insufficiencies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":60112000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94391,"accession_number":"0001628280-26-023606","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Rhythm Pharmaceuticals appoints Kim Popovits to Board; Ed Mathers resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kimberly J. Popovits elected as Class II director effective April 1, 2026 until 2028 annual meeting.","Edward T. Mathers resigned from Board same date; no disagreement with company cited.","Popovits is former Chairman/CEO of Genomic Health with >40 years life sciences experience.","Mathers served on Board since 2013; thanked for his strategic perspective and stewardship.","Popovits will receive standard non-employee director compensation per Company's policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106745,"accession_number":"0001628280-26-021414","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rhythm Pharma gets positive CHMP opinion to expand IMCIVREE label for acquired hypothalamic obesity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP recommends expanding IMCIVREE (setmelanotide) marketing authorization to treat obesity/control hunger in patients >=4 years with acquired HO due to hypothalamic injury.","European Commission decision on label expansion anticipated in Q2 2026.","Follows FDA approval last week; CEO cites broad label and global drug development approach.","Acquired HO is a rare neuroendocrine disease with impaired MC4R pathway signaling causing rapid weight gain and hyperphagia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106744,"accession_number":"0001628280-26-019995","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rhythm Pharma wins FDA approval for IMCIVREE in acquired hypothalamic obesity; Phase 3 shows -18.4% BMI reduction","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved IMCIVREE (setmelanotide) for acquired HO in adults and children 4+; first approved therapy for this indication.","Phase 3 TRANSCEND: setmelanotide (-15.8% BMI) vs placebo (+2.6%) at 52 weeks; placebo-adjusted -18.4% (p<0.0001).","Most common AEs (>20%): skin hyperpigmentation, nausea, vomiting, headache.","Rhythm estimates ~10,000 U.S. patients with acquired HO; drug available immediately.","IMCIVREE already approved for BBS and monogenic obesity due to POMC/PCSK1/LEPR deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106743,"accession_number":"0001628280-26-018211","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rhythm's Phase 3 EMANATE trial misses primary endpoints; post hoc signals in POMC/SRC1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four substudies failed primary endpoint: placebo-adjusted BMI reductions of 4.3% (POMC/PCSK1), 3.6% (LEPR), 4.0% (SRC1), 1.7% (SH2B1); all p>0.05.","Post hoc LOCF analysis showed significant BMI reductions: POMC/PCSK1 -5.5% (p=0.0010), SRC1 -6.2% (p<0.0001) vs placebo.","Completer analysis: placebo-adjusted BMI -9.7% (POMC/PCSK1, n=41, p=0.0002) and -8.0% (SRC1, n=29, p=0.0158).","Safety profile consistent with prior studies; no new signals. Common AEs: skin hyperpigmentation, injection-site reactions.","Rhythm to evaluate next-gen MC4R agonists bivamelagon and RM-718 for SRC1 and POMC; continuing DAYBREAK exploratory work."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106742,"accession_number":"0001104659-26-021801","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rhythm reports additional positive Phase 3 TRANSCEND data for setmelanotide in hypothalamic obesity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Placebo-adjusted BMI reduction of 18.8% (N=142); primary endpoint met with -16.4% BMI change on setmelanotide vs +2.4% on placebo (p<0.0001).","In patients aged 12+ (n=98), setmelanotide group showed 2.5-point reduction in weekly average most hunger score vs 1.3-point for placebo (p=0.0015).","sNDA under FDA review with PDUFA goal date of March 20, 2026; company submits final data package on March 2, 2026.","EMA reviewing Type II variation; CHMP opinion expected Q2 2026, potential EU marketing auth in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106741,"accession_number":"0001628280-26-011987","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rhythm Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results; IMCIVREE Revenue $57.3M in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 IMCIVREE revenue $57.3M, up 12% sequentially; full year revenue $194.8M vs $130.1M in 2024.","FDA PDUFA date March 20, 2026 for setmelanotide in acquired hypothalamic obesity.","Positive end-of-Phase-2 meeting with FDA for bivamelagon in acquired HO; Phase 3 trial to start by end of 2026.","Cash and investments $388.9M at Dec 31, 2025; net loss $48.8M in Q4 2025 vs $44.6M in Q4 2024.","Topline data expected March 2026 from Phase 3 EMANATE trial and Japanese cohort in acquired HO."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":189757000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106740,"accession_number":"0001628280-26-001459","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Rhythm Pharma Q4 2025 IMCIVREE revenue ~$57M (+11% QoQ); FY2025 ~$194M (+50% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net product revenue ~$57M, up 11% sequentially from Q3 2025.","FY2025 net product revenue ~$194M, a ~50% increase from $130M in FY2024.","U.S. sales contributed ~68% of Q4 and ~69% of full-year 2025 revenues.","FDA PDUFA goal date of March 20, 2026 for setmelanotide sNDA in acquired hypothalamic obesity.","Topline data from Phase 3 EMANATE trial in MC4R pathway diseases expected in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":189757000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123060,"accession_number":"0001104659-25-123108","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dr. Camille Bedrosian resigns from Rhythm Pharmaceuticals board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Camille L. Bedrosian, M.D. resigned from the Board effective December 16, 2025.","She served on the Compensation & Management Development and Governance and Nominating Committees.","Resignation not due to any disagreement with the Company or its operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123059,"accession_number":"0001104659-25-120141","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rhythm Pharma reports positive Phase 2 setmelanotide data in PWS; plans Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["18 patients enrolled; 17 remain on therapy; safety consistent with known profile.","6 of 8 patients at Month 3 achieved BMI reduction; 3 of 5 at Month 6 saw BMI reduction.","6 of 7 evaluable patients at Month 3 had meaningful hyperphagia (HQ-CT) score reduction.","Company plans to advance setmelanotide into Phase 3 registrational trial in PWS.","Initiated Phase 1 Part D of weekly MC4R agonist RM-718 in up to 20 PWS patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123058,"accession_number":"0001104659-25-108154","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA extends review of Rhythm's setmelanotide sNDA to March 20, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["New PDUFA goal date March 20, 2026, extended 3 months from December 20, 2025.","FDA requested additional sensitivity analyses of Phase 3 efficacy data; no new data required.","Major amendment classified; no safety or manufacturing issues included in the extension.","Company expresses confidence in data and continues preparations for potential launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123057,"accession_number":"0001104659-25-105904","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rhythm Q3 IMCIVREE revenue $51.3M; net loss -$0.82/sh; PDUFA Dec 20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 IMCIVREE revenue $51.3M (+6% seq, +54% YoY); US $38.2M (+19% seq).","Net loss ($54.3M) or ($0.82)/share vs ($45.0M) or ($0.73)/share a year ago.","Cash and investments $416.1M at Sep 30, 2025, up from $320.6M at Dec 31, 2024.","Updated FY2025 non-GAAP operating expense guidance $295M-$315M excluding stock-based compensation.","PDUFA date Dec 20, 2025 for setmelanotide sNDA in acquired hypothalamic obesity; Phase 2 PWS data Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":132504000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139758,"accession_number":"0001558370-25-010176","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rhythm Pharma Q2 revenue $48.5M (+29% seq), net loss $(48.0M); advances setmelanotide filings for AHO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net product revenue $48.5M, up 29% sequentially from Q1 2025; US revenue $32.0M (66% of total), up 31%.","Net loss $(48.0)M ($(0.75)/share) vs $(33.6)M ($(0.55)/share) in Q2 2024.","Cash $291M at June 30; added ~$189.2M from July stock offering; paid $40M to LG Chem for bivamelagon.","Phase 3 TRANSCEND: setmelanotide achieved placebo-adjusted BMI reduction of -19.8% in acquired hypothalamic obesity (AHO).","Regulatory submissions for setmelanotide in AHO to FDA and EMA on track for Q3 2025; FY 2025 Non-GAAP OpEx guidance $285-315M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":81206000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139757,"accession_number":"0001104659-25-067133","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rhythm Pharmaceuticals raises $188.7M in public equity offering; underwriters exercise full option","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 2,058,824 shares at $85.00 per share; underwriters exercised 30-day option for 308,823 additional shares in full.","Net proceeds expected to be approximately $188.7 million after underwriting discounts and expenses.","Proceeds to advance clinical development of product candidates and commercialization activities for IMCIVREE, plus working capital.","Company believes cash and short-term investments, including offering net proceeds, will fund operations for at least 24 months.","Underwriting agreement with Morgan Stanley and BofA Securities as representatives of the underwriters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139756,"accession_number":"0001104659-25-066724","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rhythm Pharma's bivamelagon Phase 2 meets endpoints: -9.3% BMI reduction at 14 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BMI reduction -9.3% (600mg, p=0.0004) and -7.7% (400mg, p=0.0002) vs 2.2% increase on placebo.","Mean reduction >2.8 points in 'most' hunger score on 10-point scale in 600mg and 400mg cohorts.","Safety consistent with MC4R agonism; one discontinuation due to serious AE (rectal bleeding).","Rhythm plans End-of-Phase 2 meeting with FDA and EU scientific advice for registrational path.","Data from 26 of 27 patients continued into open-label extension as of July 7, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157324,"accession_number":"0001558370-25-008924","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Rhythm stockholders elect two Class II directors, approve officer exculpation amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jennifer Good (55.6M votes for) and Edward T. Mathers (35.2M for) elected as Class II directors.","Ernst & Young ratified as independent auditor for FY2025 with 60.6M votes for, 158k against.","Non-binding advisory vote on executive compensation approved (40.9M for, 18.1M against).","Amendment to certificate of incorporation to provide officer exculpation approved (55.5M for, 3.5M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157323,"accession_number":"0001558370-25-006602","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rhythm Q1 product rev $37.7M; Phase 3 HO trial meets endpoint with -19.8% BMI reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $37.7M, up from $26.0M YoY; U.S. $24.5M, ex-U.S. $13.2M.","Net loss $50.8M ($0.81 per share) vs $141.4M ($2.35) YoY; R&D down due to prior-year acquisition cost.","Phase 3 TRANSCEND trial met primary endpoint: -19.8% placebo-adjusted BMI reduction at 52 weeks (p<0.0001); no new safety signals.","Cash and investments $314.5M as of March 31, 2025; cash runway into 2027.","Fiscal 2025 Non-GAAP operating expense guidance $285M-$315M; regulatory submissions for HO in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":32704000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157322,"accession_number":"0001558370-25-004507","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rhythm Pharma Phase 3 TRANSCEND trial meets primary endpoint with -19.8% placebo-adjusted BMI reduction in 120 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean BMI change of -16.5% on setmelanotide vs +3.3% for placebo at 52 weeks (p<0.0001); 80% achieved ≥5% BMI reduction.","Regulatory submissions in US and EU planned for Q3 2025; setmelanotide could become first approved therapy for acquired hypothalamic obesity.","Cash and short-term investments expected to fund operations into 2027.","No new safety signals; most common AEs were nausea, vomiting, diarrhea, injection site reaction, skin hyperpigmentation, headache.","Secondary endpoints: 83% of patients achieved ≥5% BMI or ≥0.2 BMI Z-score reduction; hunger score improved (p=0.003)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175699,"accession_number":"0001558370-25-003374","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["1.02","1.01","7.01","9.01"],"status":"ready","headline":"Rhythm terminates RareStone license for IMCIVREE in China; reacquires rights for $6.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Termination of 2021 Exclusive License and Share Purchase agreements with RareStone Group Ltd.","Rhythm pays $6.3M repayment of upfront payment; returns all RareStone shares for no consideration.","Reacquires full rights to IMCIVREE (setmelanotide) in mainland China, Hong Kong, and Macau.","Global trial for hypothalamic obesity on track for Q2 2025 topline data readout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175698,"accession_number":"0001558370-25-001891","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rhythm Pharmaceuticals sets June 24, 2025 annual meeting; deadline for proposals March 26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting scheduled for June 24, 2025.","Stockholder proposals and director nominations must be received by March 26, 2025.","Proposals under Rule 14a-8 must also be received by March 26, 2025.","Notices to be sent to Attention: Secretary, 222 Berkeley Street, 12th Floor, Boston, MA 02116."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175697,"accession_number":"0001558370-25-001553","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rhythm Q4 2024 IMCIVREE revenue $41.8M; cash runway extended to 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 IMCIVREE net revenue $41.8M (+26% sequential, +73% YoY); FY2024 total $130.1M.","Net loss Q4 2024 ($44.6M) or ($0.72)/share vs ($41.6M) in Q4 2023; FY loss ($264.6M).","Raised ~$75M gross proceeds from ATM (1.3M shares at ~$56.30); cash $320.6M at Dec 31, 2024.","FDA and UK MHRA expanded IMCIVREE label to children as young as 2 years old.","Phase 3 acquired hypothalamic obesity trial topline data expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":130126000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175696,"accession_number":"0001558370-25-000093","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Rhythm Pharma reports preliminary 2024 IMCIVREE sales of $130M, up 68% YoY; Phase 3 HO data on track for H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 2024 IMCIVREE net revenues of ~$42M, up 26% sequentially; full year ~$130M vs $77.4M in 2023.","U.S. sales contributed ~74% of Q4 and ~73% of full year 2024 revenues.","Topline data from Phase 3 acquired hypothalamic obesity trial expected in first half of 2025; completed Japanese cohort.","Phase 3 EMANATE enrollment completed across four substudies; topline data anticipated first half of 2026.","New Phase 2 trial of setmelanotide in Prader-Willi syndrome to initiate Q1 2025 (up to 20 patients, 26 weeks)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192640,"accession_number":"0001104659-24-114304","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rhythm Pharma Q3 revenue $33.3M (+14% seq); FDA Priority Review for label expansion to age 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IMCIVREE net revenue $33.3M (Q3 2024), up 48% YoY from $22.5M; US sales $23.3M (+8% seq), ex-US $10.0M (+35% seq).","Net loss $(45.0)M ($(0.73)/share) vs $(44.2)M ($(0.76)/share) in Q3 2023; cash $298.4M at Sep 30, 2024.","FDA accepted sNDA for Priority Review to treat children as young as 2 years; PDUFA date Dec 26, 2024.","Phase 3 hypothalamic obesity trial top-line data on track for 1H 2025; early-access French data showed 12.8% BMI reduction at 3 months.","FY 2024 non-GAAP operating expense guidance narrowed to $245-255M from $250-270M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":88296000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209091,"accession_number":"0001104659-24-101393","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rhythm Pharma shareholders elect three directors, approve equity plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class I directors: Stuart Arbuckle (45.6M for), Christophe Jean (45.0M), Lynn Tetrault (45.5M).","Ratified Ernst & Young as auditor: 53.8M for, 69.5K against.","Advisory vote on executive compensation: 50.6M for, 1.5M against.","Reapproved 2017 Equity Incentive Plan: 32.7M for, 19.4M against (63% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209090,"accession_number":"0001104659-24-086081","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rhythm Pharma Q2 2024 revenue $29.1M, up 52% YoY; net loss narrows to $33.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $29.1M vs $19.2M in Q2 2023; 74% generated in United States.","Net loss attributable to common stockholders improved to ($33.6M) or ($0.55)/share from ($46.7M) ($0.82)/share.","Cash balance $319.1M as of June 30, 2024, up from $275.8M at Dec 31, 2023; runway into 2026.","Dosed first patients in Japanese cohort for hypothalamic obesity Phase 3 trial; top-line data from pivotal cohort expected 1H 2025.","Completed sNDA submission to FDA for IMCIVREE in children age 2-6; EC already expanded to age 2 in Europe."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":55045000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209089,"accession_number":"0001104659-24-078941","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rhythm Pharmaceuticals files prospectus for resale of 3.1M shares by selling stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registration covers up to 3,124,995 common shares held by certain stockholders to satisfy registration rights.","Shares issuable upon conversion of Series A Convertible Preferred Stock sold on April 15, 2024 for $150M.","Legal opinion of Latham & Watkins filed as Exhibit 5.1 and incorporated into S-3ASR registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226940,"accession_number":"0001104659-24-072376","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rhythm Pharmaceuticals postpones 2024 annual meeting to Sept 18 due to record date error","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting postponed from June 18 to September 18, 2024; new record date July 24, 2024.","Postponement caused by a technical error in the record date used for the broker search.","Preliminary voting reports indicate quorum and all proposals would have passed if record date was correct.","No changes to proposals from definitive proxy statement filed April 26, 2024.","Stockholder proposals and director nominations must be received by June 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226939,"accession_number":"0001104659-24-057691","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rhythm Pharma Q1 net revenue $26.0M (+126% YoY); net loss $141.4M on $92.4M LB54640 charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $26.0M (Q1 2023: $11.5M); 74% from U.S. sales.","Net loss $141.4M ($2.35/share) vs $52.2M ($0.92/share) prior year; R&D spend $128.7M incl $92.4M IPR&D for LB54640.","Cash $201M at March 31; closed $150M preferred stock financing April 15 extending runway into 2026.","On track to submit sNDA for IMCIVREE in pediatric patients 2 to <6 years old in Q2 2024.","Phase 3 hypothalamic obesity trial top-line data expected H1 2025; Japanese cohort dosing starts Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":25967000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226938,"accession_number":"0001104659-24-047492","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Rhythm Pharmaceuticals closes $150M Series A Convertible Preferred issuance to Perceptive affiliates","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed on April 15, 2024; issued 150,000 shares at $1,000 each for aggregate $150,000,000.","Convertible Preferred ranks senior to common; liquidation preference initially $1,000, rises to 175% on change of control.","Dividend rate: 0% for first two years, then 6% per annum (PIK or cash at Company's election), compounded quarterly.","Registration rights granted to investors for shares issuable upon conversion of Convertible Preferred.","No dividends on common stock unless equivalent dividend declared on Convertible Preferred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226937,"accession_number":"0001104659-24-041970","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Rhythm Pharma raises $150M in convertible preferred stock; conversion at $48 (19% premium)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$150M gross proceeds from sale of Series A Convertible Preferred Stock to Perceptive and other existing shareholders.","Initial conversion price of $48 per share, representing a 19% premium to the 10-day VWAP.","Cash runway extended into 2026; includes existing cash and net proceeds from the offering.","Preferred stock pays 6% cumulative annual dividend starting year 2, payable PIK or cash at company's option.","Convertible after HSR waiting period; company can force conversion if stock >250% of conversion price for 20 of 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245890,"accession_number":"0001104659-24-029417","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Rhythm Pharmaceuticals amends sales agreement to allow up to $200M in at-the-market stock offerings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment increases ATM offering limit from $100M to $200M, excluding $50M already sold.","Company had $50M in prior sales as of Feb 29, 2024; new capacity starts from zero.","No specific use of proceeds disclosed; typical for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245889,"accession_number":"0001104659-24-026303","cik":1649904,"company_name":"RHYTHM PHARMACEUTICALS, INC.","ticker":"RYTM","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Rhythm Pharma Q4 IMCIVREE rev $24.2M; reports material weakness in IT controls","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net product revenue $24.2M (FY2023 $77.4M) vs $8.8M Q4 2022; net loss $41.6M ($0.70/share).","Cash $275.8M at Dec 31, 2023; 2024 non-GAAP op expense guidance $250-270M.","Material weakness in IT general controls over user access and program change management expected in 10-K.","Completed enrollment in Phase 3 hypothalamic obesity trial (N=120); top-line data 1H2025.","Entered global licensing deal for oral MC4R agonist LB54640; IND accepted for RM-718."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":77428000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6307055791.063553,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}